Antigenicity of Human Melanoma Cells Transfected to Express the B7-1 Co-Stimulatory Molecule (CD80) Varies with the Level of B7-1 Expression
Format of Original
Cancer Immunology and Immunotherapy
Original Item ID
The aim of this study was to compare the antigenicity of human melanoma cells molecularly modified by particle-mediated gene transfer to have transient or stable expression of the B7-1 co-stimulatory molecule (CD80). The unmodified melanoma cells (mel5, m21) had no constitutive expression of B7-1, but 22%–28% of cells had transient B7-1 expression 24 h following transfection with cDNA for B7-1 (mel5-B7, m21-B7). In addition, 85%–90% of cells had stable B7-1 expression following transfection with cDNA for B7-1 and in vitro culture under selection conditions (mel5-B7neo, m21-B7neo). Allogeneic HLA-unmatched normal donor peripheral blood mononuclear cells (PBMC) secreted greater amounts of granulocyte/macrophage-colony-stimulating factor (GM-CSF) when incubated for 3 days with m21-B7neo than did PBMC incubated with m21-B7, which, in turn, secreted greater amount of GM-CSF than PBMC incubated with m21. Similarly, cell-mediated cytotoxicity against unmodified melanoma cells by PBMC co-cultured for 5 days with the modified or unmodified melanoma cells was proportional to the level of B7-1 expression on the stimulating cells. This cytolytic activity had both an HLA-class-I-restricted and an HLA-class-I-unrestricted component. Following 5 days of co-culture, PBMC expression of CD28, the ligand for B7-1, was down-regulated in proportion to the level of B7-1 expression on the stimulating melanoma cells. Thus, particle-mediated gene delivery of cDNA for B7-1 into human melanoma cells increased expression of functional B7-1 and enhanced the antigenicity of the gene-modified cells in proportion to their level of B7-1 expression.
McCarthy, Donna O.; Glowacki, Nicole; Schell, Kathleen; Emler, Carol A.; and Albertini, Mark R., "Antigenicity of Human Melanoma Cells Transfected to Express the B7-1 Co-Stimulatory Molecule (CD80) Varies with the Level of B7-1 Expression" (2000). College of Nursing Faculty Research and Publications. 225.
Cancer Immunology and Immunotherapy, Vol. 49, No. 2 (April 2000): 85-93. DOI.
Shareable Link. Provided by the Springer Nature SharedIt content-sharing initiative.